EO2 oxygen delivery system demonstrates benefits for diabetic foot ulcer treatment

100
EO2 oxygen delivery
EO2 System

EO2 Concepts has announced the publication of a post hoc analysis from its randomised, double-blinded, multi-centre study, published last year in the Journal of Wound Care. This latest study evaluates the positive impact which continuous diffusion of oxygen (CDO), with the wearable EO2 Oxygen Delivery System (EO2 System), has on patients suffering from diabetic foot ulcers when coupled with frequent wound debridement.

Results of the investigation, which enrolled 146 patients, demonstrate that a significantly higher percentage of wound closure is achieved in patients receiving active CDO therapy, compared to those receiving a placebo device in addition to standard wound care with identical dressings, debridement recommendations and offloading. Sites that debrided ulcers in nearly every visit experienced a 240% improvement in the treatment arm over the placebo arm, supporting the importance of debridement as a component of the overall diabetic foot ulcer treatment strategy.

“These results confirm that frequent debridement allows for greater access of the continuous flow of oxygen to the affected tissues, supporting enhanced wound healing,” stated Lawrence A Lavery (Dallas, USA), DPM, MPH, co-author on the publication and professor of Plastic Surgery at University of Texas Southwestern Medical Center. He added: “This builds on the body of evidence that aggressive debridement facilitates wound healing.”

David G Armstrong, professor of Surgery and director of the Southwestern Academic Limb Salvage Alliance (SALSA) at University of Southern California also commented: “This therapy now has undergone a rigorous randomised controlled trial, where the data were not only surprising, but compelling. I think that this therapy should now be considered as a potential adjunct for optimising the wound healing environment once the wound has received good quality debridement and offloading.”

Diabetic foot ulcers are a common complication associated with the worldwide epidemic of diabetes, leading to amputations and hospitalisations. The wearable EO2 System is the world’s first wound healing technology that continuously delivers, and monitors the delivery of, precise levels of pure, humidified oxygen to effect full wound closure.

Results from its randomised, double-blinded study demonstrate that CDO therapy with the EO2 System substantially improves the healing process in chronic wounds by providing faster, complete healing, particularly in patients with more complex wounds. Current data suggests that the relative performance of CDO appears to increase with the use of frequent debridement.

“We have anecdotally believed that more frequent debridement in combination with the known benefits of CDO therapy and this data supports those assertions,” stated Joe Moffett, President of EOConcepts. “These results will help to support current guidelines and improve outcomes in this highly underserved patient population.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here